Foresite Capital Opportunity Management V, LLC

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Reported portfolio value by quarter (4 quarters reported)

$149M $33.3M

Q4 21 Q1 22 Q2 22 Q3 22

$149M in Q4 2021 → $33.3M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2022. Activity is the change in share count since the prior quarter's filing.

Holding	% of portfolio	Activity	Shares	Value
PB Pardes Biosciences Inc	29.0%	Unchanged	5,227,307	$9.67M
Theseus Pharmaceuticals, Inc.	16.7%	Unchanged	959,275	$5.56M
GT Gemini Therapeutics, Inc.	12.0%	Unchanged	2,435,125	$3.99M
Compass Therapeutics, Inc.	10.6%	Unchanged	1,554,250	$3.54M
Kinnate Biopharma Inc.	10.5%	Unchanged	291,667	$3.49M
Adicet Bio, Inc.	7.3%	Unchanged	170,000	$2.42M
Quantum-si Incorporated	5.2%	Unchanged	633,626	$1.74M
Hims & Hers Health, Inc.	5.1%	Unchanged	306,431	$1.71M
Enanta Pharmaceuticals, Inc.	3.5%	Unchanged	22,750	$1.18M

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.

quarter ended September 30, 2022 · filed November 14, 2022

No position changes this quarter.

quarter ended June 30, 2022 · filed August 12, 2022

Company	Action	Shares changed	Value of change	% of portfolio
Cue Health Inc.	Exited	−641,483	−$4.14M	—
CO Cullinan Oncology, Inc.	Exited	−330,836	−$3.46M	—
Theseus Pharmaceuticals, Inc.	Added	+490,455	+$2.71M	13.4%
Quantum-si Incorporated	Trimmed	−964,499	−$2.24M	3.7%
Hims & Hers Health, Inc.	New	+306,431	+$1.39M	3.5%
Compass Therapeutics, Inc.	Added	+454,250	+$1.2M	10.4%

quarter ended March 31, 2022 · filed May 13, 2022

Company	Action	Shares changed	Value of change	% of portfolio
Cue Health Inc.	Trimmed	−885,620	−$5.71M	5.8%
Enanta Pharmaceuticals, Inc.	New	+22,750	+$1.62M	2.3%
CO Cullinan Oncology, Inc.	Trimmed	−50,166	−$525K	4.9%

Comments